No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 10.5x · 10Y median 941.3x · 8th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 19
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:15:45.959Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T11:15:45.959Z. Latest historical point 2026-08-13. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T11:15:45.959Z. Latest historical point 2022-05-16. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T11:15:45.959Z. Latest historical point 2022-05-16. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T11:15:45.959Z. Latest historical point 2026-08-13. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Aspire Biopharma Holdings, Inc. (ASBP) stock was $8.88 as of Oct 5, 2026, 4:00 PM EDT, up 1.14% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -98.0% · 3-year avg -91.1%/yr
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States.
Biotechnology · Estero, FL
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.00
vs Estimate
N/A
Revenue
$63103.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ASBP | $1.02M | $8.88 | +1.14% | -98.04% | N/A | N/A | N/A |
| 2CMND | $1.11M | $6.00 | +4.90% | -99.81% | N/A | N/A | vs ASBP |
| 3DCOY | $888,387 | $1.67 | -5.65% | -96.49% | -86.39% | -79.17% | vs ASBP |
| 4BBLG | $878,396 | $0.49 | +2.06% | -80.44% | N/A | N/A | vs ASBP |
| 5BJDX | $787,624 | $0.76 | -9.01% | -87.52% | N/A | N/A | vs ASBP |
| 6CDT | $707,297 | $0.92 | -7.30% | N/A | N/A | N/A | vs ASBP |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$8.88
High
N/A
